If you have been reading about pharmacokinetics and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-07-05. Numbers and descriptions here follow the published literature rather than marketing material.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, with mass spectrometry used to confirm molecular mass and sequence information. Amino acid analysis and peptide mapping may supplement these methods. Certified reference standards are scarce, and many commercial lots are sold as research chemicals without a pharmacopoeial monograph. Regulatory treatment differs by country: Selank is a registered prescription medicine in Russia, while in the European Union and the United States it is not an approved drug and may fall under research-chemical or unapproved-product frameworks.
Selank is a hydrophilic peptide and dissolves readily in water and in aqueous buffers. The lyophilised powder is typically a white to off-white solid. Because short peptides are prone to hydrolysis and oxidation, handling benefits from limiting exposure to heat, moisture and strong light. Working solutions are commonly prepared in sterile water or saline, and repeated freeze-thaw cycles are avoided to reduce aggregation and loss of activity. These practices reflect general laboratory convention rather than published stability specifications.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilised solid form |
| Solubility class | Freely soluble in water | Hydrophilic heptapeptide |
| Dry storage temperature | -20 degrees Celsius or lower | Sealed, desiccated, protected from light |
| Solution storage | 2 to 8 degrees Celsius short term | Avoid repeated freeze-thaw cycles |
| Common identification method | Reversed-phase HPLC with mass spectrometry | Confirms purity and molecular mass |
Lyophilized Selank, the dry powder form, is generally stored frozen at minus 20 degrees Celsius or colder for long-term keeping. The solid is hygroscopic and should stay sealed, dry, and protected from light. Once dissolved, the peptide is less stable and is usually held refrigerated at 2 to 8 degrees Celsius for short periods. Repeated freezing and thawing is avoided because it can promote aggregation and loss of activity. Buffers and pH choice also affect how long a solution remains usable.
Solubility behavior is a practical concern for handling. Selank dissolves readily in water and in common aqueous buffers, which simplifies preparation of working solutions. The choice of solvent, ionic strength, and pH can influence aggregation over time, particularly at higher concentrations. Aqueous solutions are typically sterile-filtered before use. Because stability depends on several variables, storage and handling notes should be treated as general guidance rather than fixed rules, and specific values are best confirmed against a certificate of analysis for each batch.
Characterization of Selank in a laboratory setting relies on standard peptide methods. Reverse-phase high-performance liquid chromatography separates the target from related impurities and provides a purity figure, commonly reported as 95 percent or higher. Mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, confirms the molecular mass and helps detect truncation or modification. Amino acid analysis can verify composition when a sequence-level check is needed. These techniques together establish identity and purity for a given lot.
Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.
The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.
Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.
Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
== Biological control of nematodes == This fungus has been investigated as a biocontrol agent of agriculturally important nematodes, most notably those responsible for gastrointestinal infection of grazing animals. These parasitic infections are commonly treated with anthelmintic agents including benimidazole, levamisole and invermectin. However, increasing levels of anthelmintic resistance have been observed, driving the search for new treatment and prevention options. Larvae of animal-pathogenic nematodes are found in soil. The prospect of treating contaminated soils with nematode pathogenic fungi such as H. anguillulae has shown potential to reduce nematode populations. However, the fungus does not persist in soil following the elimination of nematode populations, potentially limiting its use as a sustainable biocontrol agent.
The Northern Ireland Executive is restored after the DUP ends its two-year boycott; Sinn Féin's Michelle O'Neill is appointed First Minister, becoming the first nationalist politician to hold the post, while the DUP's Emma Little-Pengelly is appointed deputy. A third round of joint UK–US air strikes are launched against Houthi rebels, targeting three sites in Yemen. Defence Secretary Grant Shapps says the latest strikes are "not an escalation" of the conflict. Esther Martin, a 68-year-old woman, is killed by dogs while visiting her grandson for the weekend in Jaywick, near Clacton-on-Sea, Essex. 4 February – CCTV footage of alkali attack suspect Abdul Shakoor Ezedi in a Tesco store is shown by the police, as a reward of £20,000 is offered for information leading to his capture. 5 February Buckingham Palace announces that King Charles III has been diagnosed with cancer and will postpone public duties while undergoing treatment. The Met Office issues a yellow weather warning for snow for large parts of north Wales, and northern and central England, for 8 February as unseasonably mild temperatures are replaced by colder weather. A 16-year-old boy is found guilty of plotting to launch a terrorist attack at the Isle of Wight Festival following a trial at Kingston Crown Court. The UK government launches a six-week consultation on plans for Martyn's Law, which would make provisions to better protect the public against potential acts of terrorism.
=== Cancers === Lung cancer can either arise directly from lung tissue or as a result of metastasis from another part of the body. There are two main types of primary tumour described as either small-cell or non-small-cell lung carcinomas. The major risk factor for cancer is smoking. Once a cancer is identified it is staged using scans such as a CT scan and a sample of tissue from a biopsy is taken. Cancers may be treated surgically by removing the tumour, the use of radiotherapy, chemotherapy or a combination, or with the aim of symptom control. Lung cancer screening is being recommended in the United States for high-risk populations.
== Diagnosis == The diagnosis of MADD needs to be considered in patients who have exercise induced myalgia, cramps and sometimes weakness. A mildly elevated creatine kinase may also occur. Exclusion of other muscular diseases such as McArdle's Disease and carnitine cycle abnormalities should occur. MADD may be identified if there is a lack of ammonia rise after forearm exercise testing. The diagnosis may then be confirmed with genetic testing.
Despite their cultural depictions as "swimming dinosaurs", mosasaurs, ichthyosaurs, plesiosaurs, and other aquatic Mesozoic diapsids were not dinosaurs. Mosasaurs were actually lizards, and ichthyosaurs and plesiosaurs were even more distantly related to dinosaurs. Though some dinosaurs were or are semiaquatic (Hesperornis, Spinosaurus, auks, penguins), none are known to have been fully marine. Pterosaurs (informally called pterodactyls) are often called "flying dinosaurs" by popular media and the general public, but while pterosaurs were closely related to dinosaurs, dinosaurs are defined as the descendants of the last common ancestor of the Saurischia and the Ornithischia, which excludes the pterosaurs. Dimetrodon is often mistakenly called a dinosaur or considered to be a contemporary of dinosaurs in popular culture, but it became extinct some 40 million years before the first appearance of dinosaurs. Being a synapsid, Dimetrodon is actually more closely related to mammals than to dinosaurs, lizards, or other diapsids. Humans and non-avian dinosaurs did not coexist at any point, although humans and avian dinosaurs currently coexist. The last of the non-avian dinosaurs died 66 million years ago in the Cretaceous–Paleogene extinction event while the earliest members of the genus Homo (humans) evolved between 2.3 and 2.4 million years ago. With the exception of a tiny amount of the world's coal, fossil fuels such as petroleum and coal do not originate from dinosaur fossils.
Sources: en.wikipedia.org
Increased entry of megakaryocytes into the systemic circulation. Under normal circumstances in healthy individuals, megakaryocytes that arise from the bone marrow are trapped in the pulmonary capillary bed and broken down before entering the systemic circulation. In disorders where there is prominent extrapulmonary shunting of blood (e.g. cyanotic heart diseases, liver cirrhosis), the megakaryocytes can bypass the breakdown within the pulmonary circulation and enter the systemic circulation. They are then trapped within the capillary beds within the extremities, such as the digits, and release PDGF and VEGF. In cases or diffuse pulmonary diseases or lung cancer, the excess VEGF produced in the diseased parts of the lungs directly enter circulation. Hypoxia induces the expression of VEGF by platelets. It also enhances the release of PFGF and VEGF by megakaryocytes. Other causes of platelet and/or endothelial cell activation, including: Overproduction of prostaglandin E by other tissues, such as in lung cancer and Crohn's disease. This is usually linked to higher levels of COX-2. Underconsumption of prostaglandin E by other tissues, such as in HPGD and/or SLCO2A1 mutations (pachydermoperiostosis, see above). Use of prostaglandin E medication. A chronic excess of platelets, such as in inflammatory bowel disease. In thyroid acropachy, the explanation leans autoimmune and probably involves a process similar to thyroid eye disease, with increased proliferation of fibroblasts and deposition of glycosamines.
aurantium, whereas a close reading of the text of the paper itself reveals that the authors (although apparently uncertain about which synephrine regio-isomer had been found in the plant by earlier investigators) were aware that their analytical technique could not distinguish between m- and p-synephrine, and did not claim that m-synephrine was present. Thus the Abstract is at variance with the experimental findings given in the full text of the paper, but this error has propagated through subsequent publications. Even the name "p-synephrine" is not unambiguous, since it does not specify stereochemistry. The only completely unambiguous names for synephrine are: (R)-(−)-4-[1-hydroxy-2-(methylamino)ethyl]phenol (for the l-enantiomer); (S)-(+)-4-[1-hydroxy-2-(methylamino)ethyl]phenol (for the d-enantiomer); and (R,S)-4-[1-hydroxy-2-(methylamino)ethyl]phenol (for the racemate, or d,l-synephrine) (see Chemistry section).
==== Monoamine releasing agent ==== Phenethylamine, being similar to amphetamine in its action at their common biomolecular targets, is a releasing agent of norepinephrine and dopamine. It is roughly equipotent to amphetamine in this regard in vitro. Phenethylamine is inactive as a psychostimulant under normal circumstances due to rapid metabolism by monoamine oxidase (MAO), but can become active in the presence of a monoamine oxidase inhibitor (MAOI).
A placebo is an inactive pill, liquid, or powder that has no treatment value. In clinical trials, experimental treatments are often compared with placebos to assess the treatment's effectiveness. (NLM) An inactive substance or treatment that looks the same as, and is given the same way as, an active drug or treatment being tested. The effects of the active drug or treatment are compared to the effects of the placebo. (NCI) Placebo controlled study
Sources: en.wikipedia.org
Dry powder is normally held at -20 degrees Celsius or below in a sealed, light-protected container with desiccant. Brief room-temperature handling during weighing is generally tolerated. Storage instructions vary between suppliers, so the accompanying certificate of analysis should be followed.
Reversed-phase HPLC establishes purity, while mass spectrometry confirms the expected molecular mass. Sequence confirmation may use tandem mass spectrometry or peptide mapping. A certificate of analysis typically reports these results alongside the analytical method applied.
In Russia it is a registered medicine available by prescription. In many other countries it is not approved for human use and is supplied only as a research chemical. Import and possession rules differ by jurisdiction, and buyers are responsible for checking local requirements.
Intranasal administration predominates in both animal and human research because it avoids hepatic first-pass metabolism. Injectable and intraperitoneal routes appear in animal work mainly for comparison.